RIGL biotech catalysts & pipeline

RIGEL PHARMACEUTICALS INC · Data as of 2026-10-27

Upcoming catalysts

R289 — Initial data

by year end

We are also advancing the development of R289 in our ongoing Phase 1b study in patients with R/R lower-risk MDS, and remain on track to complete enrollment in the dose expansion phase of the study, select a recommended Phase 2 dose in the second half of 2026 and share preliminary data by year end.

Source filing

GAVRETO (pralsetinib) — Conference presentation

Oct 23–Oct 27

Health-Related Quality of Life (HRQoL) Among Patients With Advanced or Metastatic RET -Fusion-Positive NSCLC Treated With Pralsetinib in ARROW Giuseppe Curigliano, MD, PhD ePoster Presentation #2808eP N/A N/A

Source filing

Explore the free biotech catalyst calendar